1. Home
  2. MIRM vs KNF Comparison

MIRM vs KNF Comparison

Compare MIRM & KNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$100.65

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Logo Knife Riv Holding Co.

KNF

Knife Riv Holding Co.

HOLD

Current Price

$80.79

Market Cap

4.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
KNF
Founded
2018
1917
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.2B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MIRM
KNF
Price
$100.65
$80.79
Analyst Decision
Strong Buy
Buy
Analyst Count
11
8
Target Price
$102.64
$95.88
AVG Volume (30 Days)
733.0K
663.6K
Earning Date
02-26-2026
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.61
Revenue
$471,794,000.00
$3,048,164,000.00
Revenue This Year
$55.91
$8.80
Revenue Next Year
$23.97
$5.90
P/E Ratio
N/A
$30.87
Revenue Growth
53.66
5.52
52 Week Low
$36.88
$58.72
52 Week High
$105.74
$105.99

Technical Indicators

Market Signals
Indicator
MIRM
KNF
Relative Strength Index (RSI) 64.68 59.78
Support Level $97.49 $66.88
Resistance Level $105.74 $80.48
Average True Range (ATR) 3.71 2.93
MACD -0.79 0.89
Stochastic Oscillator 62.01 92.18

Price Performance

Historical Comparison
MIRM
KNF

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About KNF Knife Riv Holding Co.

Knife River Holding Co is an aggregates-led construction materials and contracting services provider. Its segments include Pacific, Northwest, Mountain, North Central, South, and Energy Services. Each geographic segment offers a vertically integrated suite of products and services, including aggregates, ready-mix concrete, asphalt, and contracting services, while the Energy Services segment, which has locations throughout the company's geographic footprint, produces and supplies liquid asphalt and related services, for use in asphalt road construction, and is a supplier to some of the other segments.

Share on Social Networks: